Daewoong Pharmaceutical and Hanall Biopharma have confirmed the request to test the anti-Tumour Necrosis Factor (TNF) antibody as a way of treating patients with excessive tear evaporation or the inability to produce tears.The companies say that HL036 should have a significant impact on DED because it has enhanced tissue distribution properties, stability and activity compared to conventional antibodies.{{quote-A:R-W:450-I:2-Q: The synergy plans that have been prepared and carried out during the third year of joint managent are leading to success in each division, -WHO:Mr Park Seung-guk, CEO of Hanall}}Hanall became a subsidiary of Daewoong in 2015, and the two companies have merged multiple research and development projects following the acquisition.“The synergy plans that have been prepared and carried out during the third year of joint managent are leading to success in each division,” Hanall CEO Mr Park Seung-guk told Korea Biomedical Review.“In particular, we were able to strengthen our global capabilities by concentrating research funding on biologics such as antibody drugs and R&D.”According to Park, the collaboration has led to breakthrough developments in immunotherapy treatments for cancer, which could also benefit diseases such as optic neuritis and myasthenia gravis.The company aims to begin phase 1 clinical trials in Australia by the last quarter of 2017.
Gov’s aged care reform needs funding clarity
The Government’s Aged Care Act 2024 is a welcome commitment to the country’s older citizens, but a lack of clarity...
